AGP
Artia Global Partners Portfolio holdings
AUM
$389M
This Quarter Return
-4.26%
1 Year Return
+34.68%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$248M
AUM Growth
+$248M
(-30%)
Cap. Flow
-$66M
Cap. Flow
% of AUM
-26.6%
Top 10 Holdings %
Top 10 Hldgs %
65.48%
Holding
54
New
8
Increased
11
Reduced
3
Closed
19
Top Buys
| 1 |
Arcellx
ACLX
|
$17.6M |
| 2 |
Merus
MRUS
|
$16.1M |
| 3 |
Nuvalent
NUVL
|
$14.8M |
| 4 |
Soleno Therapeutics
SLNO
|
$9.89M |
| 5 |
Janux Therapeutics
JANX
|
$8.73M |
Top Sells
| 1 |
Eli Lilly
LLY
|
$82M |
| 2 |
Novo Nordisk
NVO
|
$46.6M |
| 3 |
Viking Therapeutics
VKTX
|
$17.8M |
| 4 |
Vertex Pharmaceuticals
VRTX
|
$8.79M |
| 5 |
Axsome Therapeutics
AXSM
|
$7.89M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Soleno Therapeutics
SLNO
$3.6B
| $22.2M | 7.94% |
494,424
+220,000
| +80% | +$9.89M |
|
|
2
Merus
MRUS
$4.98B
| $19.5M | 6.97% |
463,840
+383,669
| +479% | +$16.1M |
|
|
ITCI
3
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $18.4M | 6.56% |
219,719
+3,200
| +1% | +$267K |
|
|
4
Arcellx
ACLX
$3.85B
| $17.6M | 6.3% |
+229,785
| New | +$17.6M |
|
|
5
Novo Nordisk
NVO
$251B
| $17.2M | 6.15% |
200,000
-541,743
| -73% | -$46.6M |
|
|
6
Nuvalent
NUVL
$5.52B
| $16M | 5.71% |
204,045
+188,608
| +1,222% | +$14.8M |
|
7
Vaxcyte
PCVX
$4B
| $13.3M | 4.75% |
162,255
+86,000
| +113% | +$7.04M |
|
8
Alnylam Pharmaceuticals
ALNY
$58.5B
| $13.3M | 4.74% |
56,400
+21,400
| +61% | +$5.04M |
|
9
AstraZeneca
AZN
$248B
| $12.5M | 4.47% |
190,752
| – | – |
|
10
Revolution Medicines
RVMD
$7.1B
| $12.4M | 4.44% |
284,190
+188,305
| +196% | +$8.24M |
|
|
VRNA
11
Verona Pharma
VRNA
$9.16B
| $11.9M | 4.24% |
255,318
+106,728
| +72% | +$4.96M |
|
12
Insmed
INSM
$28.8B
| $11.6M | 4.14% |
167,939
+115,000
| +217% | +$7.94M |
|
13
Protagonist Therapeutics
PTGX
$3.67B
| $11.3M | 4.05% |
293,851
+169,411
| +136% | +$6.54M |
|
|
14
Janux Therapeutics
JANX
$1.37B
| $8.73M | 3.12% |
+162,976
| New | +$8.73M |
|
15
argenx
ARGX
$43.6B
| $6.96M | 2.49% |
11,311
-3,827
| -25% | -$2.35M |
|
16
Neurocrine Biosciences
NBIX
$13.8B
| $6.14M | 2.2% |
45,000
| – | – |
|
|
17
Viking Therapeutics
VKTX
$3.04B
| $3.63M | 1.3% |
90,279
-442,600
| -83% | -$17.8M |
|
18
Rhythm Pharmaceuticals
RYTM
$6.85B
| $2.8M | 1% |
+50,000
| New | +$2.8M |
|
19
Crinetics Pharmaceuticals
CRNX
$2.92B
| $2.34M | 0.84% |
45,765
| – | – |
|
20
Enliven Therapeutics
ELVN
$1.2B
| $2.32M | 0.83% |
+102,900
| New | +$2.32M |
|
|
SWTX
21
DELISTED
SpringWorks Therapeutics
SWTX
| $1.95M | 0.7% |
53,930
| – | – |
|
22
Viridian Therapeutics
VRDN
$1.5B
| $1.92M | 0.69% |
+100,000
| New | +$1.92M |
|
23
TG Therapeutics
TGTX
$4.65B
| $1.64M | 0.59% |
+54,515
| New | +$1.64M |
|
24
EyePoint Pharmaceuticals
EYPT
$797M
| $1.61M | 0.58% |
216,700
+60,400
| +39% | +$450K |
|
25
Xenon Pharmaceuticals
XENE
$2.98B
| $1.57M | 0.56% |
40,000
| – | – |
|